SEC Form 4 · accession 0001144204-15-014248
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Binh Nguyen
Officer — VP of Medical Affairs
Period of report
Mar 3, 2015
Accepted (ET)
Mar 5, 2015 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 3, 2015 | M | 40,000 | $3.55 | A | 58,242 | D | |
| Common StockF1,F2 | Mar 3, 2015 | S | 29,883 | $5.7888 | D | 28,359 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.55 | Mar 3, 2015 | M | 40,000 | D | — | Feb 28, 2022 | Common Stock | 40,000 | 20,000 | D |
Explanation of responses
- F1Shares sold to cover option exercise cost, taxes and fees.
- F2Represents the sale of 29,883 shares in multiple transactions, ranging in price from $5.72 to $5.91 per share, resulting in a weighted average sale price of $5.7888. The reporting person will provide, upon request by the SEC staff, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F3Shares subject to the option vest annually over a four (4) year period beginning on March 1, 2013.